Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -98.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $61 | $41 | $39 | $24 |
| G&A Expenses | $23 | $18 | $22 | $17 |
| SG&A Expenses | $23 | $18 | $22 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $84 | $59 | $61 | $42 |
| Operating Income | -$83 | -$59 | -$61 | -$34 |
| % Margin | – | – | -1,011,633.3% | -7,478.5% |
| Other Income/Exp. Net | $7 | $2 | $0 | $8 |
| Pre-Tax Income | -$75 | -$58 | -$61 | -$33 |
| Tax Expense | $0 | -$2 | -$2 | -$8 |
| Net Income | -$75 | -$58 | -$61 | -$33 |
| % Margin | – | – | -1,011,533.3% | -7,378.5% |
| EPS | -3.96 | -5.07 | -5.31 | -3.2 |
| % Growth | 21.9% | 4.5% | -65.9% | – |
| EPS Diluted | -3.96 | -5.07 | -5.5 | -3.2 |
| Weighted Avg Shares Out | 19 | 11 | 11 | 10 |
| Weighted Avg Shares Out Dil | 19 | 11 | 11 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $2 | $0 | $0 |
| Interest Expense | -$0 | $2 | $0 | $0 |
| Depreciation & Amortization | $0 | $3 | $2 | -$14 |
| EBITDA | -$83 | -$53 | -$61 | -$48 |
| % Margin | – | – | -1,011,633.3% | -10,546.3% |